JP2018500004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500004A5 JP2018500004A5 JP2017521534A JP2017521534A JP2018500004A5 JP 2018500004 A5 JP2018500004 A5 JP 2018500004A5 JP 2017521534 A JP2017521534 A JP 2017521534A JP 2017521534 A JP2017521534 A JP 2017521534A JP 2018500004 A5 JP2018500004 A5 JP 2018500004A5
- Authority
- JP
- Japan
- Prior art keywords
- mhc
- peptide
- ligand
- peptide ligand
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097994P | 2014-12-30 | 2014-12-30 | |
| US62/097,994 | 2014-12-30 | ||
| GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB1423361.3 | 2014-12-30 | ||
| PCT/EP2015/079873 WO2016107740A1 (en) | 2014-12-30 | 2015-12-15 | Method for the absolute quantification of naturally processed hla-restricted cancer peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500004A JP2018500004A (ja) | 2018-01-11 |
| JP2018500004A5 true JP2018500004A5 (enExample) | 2018-03-08 |
| JP6735741B2 JP6735741B2 (ja) | 2020-08-05 |
Family
ID=52471641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521534A Active JP6735741B2 (ja) | 2014-12-30 | 2015-12-15 | 自然にプロセスされたｈｌａ拘束性がんペプチドを絶対的定量化する方法 |
Country Status (35)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| TWI755157B (zh) * | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| HK1258386A1 (zh) | 2015-10-05 | 2019-11-08 | Immatics Biotechnologies Gmbh | 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物 |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| US11464800B2 (en) * | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| KR102731127B1 (ko) | 2018-09-05 | 2024-11-18 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| CN114303060A (zh) | 2019-06-06 | 2022-04-08 | 伊玛提克斯生物技术有限公司 | 使用序列相似肽进行反向选择分选 |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| EP4010708A1 (en) | 2019-08-09 | 2022-06-15 | Immatics US, Inc. | Methods for peptide mass spectrometry fragmentation prediction |
| US12480958B2 (en) * | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for propagating t cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| EP4153633A1 (en) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Mageb2 binding constructs |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| TW202321277A (zh) | 2021-07-27 | 2023-06-01 | 德商英麥提克生物技術股份有限公司 | 特異性結合ｃｔ４５之抗原結合蛋白 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| UY39967A (es) | 2021-10-06 | 2023-05-15 | Immatics Biotechnologies Gmbh | Indicaciones para los aglutinantes anti-PRAME |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| WO2025040598A2 (en) | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025125536A1 (en) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Absolute copy number prediction of mhc-presented peptides by relative quantitative measurement |
| WO2025125535A1 (en) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Differential population-scale immunopeptidomics |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| WO2026008886A1 (en) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
| WO2026033136A1 (en) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Advanced treatment modalities for anti-prame tcr-engineered immune cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1425586E (pt) | 2001-09-14 | 2007-12-31 | Electrophoretics Ltd | Marcadores de massa |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
| CA2517580A1 (en) * | 2002-11-08 | 2004-05-21 | Hiroshi Takahashi | Method of examining cancer cells and reagent therefor |
| WO2005076009A2 (en) | 2004-01-28 | 2005-08-18 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumour-associated peptides |
| JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US20140051092A1 (en) | 2011-04-15 | 2014-02-20 | Micromass Uk Limited | Method And Apparatus For The Analysis Of Biological Samples |
| WO2012178030A2 (en) | 2011-06-24 | 2012-12-27 | Applied Isotope Technologies, Inc. | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening |
| US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| FI3707159T3 (fi) * | 2017-11-06 | 2023-04-18 | Immatics Biotechnologies Gmbh | Uusia muokattuja t-solureseptoreita ja niitä käyttävä immuuniterapia |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 MX MX2017008722A patent/MX383806B/es unknown
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh not_active Expired - Fee Related
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 CA CA2972306A patent/CA2972306C/en active Active
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh not_active IP Right Cessation
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/en active Active
- 2015-12-15 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active Active
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en active Active
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/en not_active Ceased
-
2017
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
-
2024
- 2024-04-18 US US18/638,970 patent/US20240280583A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500004A5 (enExample) | ||
| HRP20210811T1 (hr) | Metoda apsolutne kvantifikacije prirodno prerađenih peptida raka ograničenih na hla | |
| Soekmadji et al. | The future of Extracellular Vesicles as Theranostics–an ISEV meeting report | |
| Zhang et al. | High-throughput determination of the antigen specificities of T cell receptors in single cells | |
| Nixon et al. | Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? | |
| Casagrande et al. | Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs | |
| Wendisch et al. | SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis | |
| Zhu et al. | DPHL: a DIA pan-human protein mass spectrometry library for robust biomarker discovery | |
| Hüttenhain et al. | Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics | |
| Dear et al. | Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling | |
| Khodadoust et al. | Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens | |
| Wu et al. | Classification of circulating tumor cells by epithelial-mesenchymal transition markers | |
| Blatnik et al. | A targeted LC‐MS strategy for low‐abundant HLA class‐I‐presented peptide detection identifies novel human papillomavirus T‐cell epitopes | |
| Graessel et al. | A combined omics approach to generate the surface atlas of human naive CD4+ T cells during early T-cell receptor activation | |
| Xiao et al. | Quantitative proteomic analysis of microdissected oral epithelium for cancer biomarker discovery | |
| KR20170104154A (ko) | 샘플과 연관된 폴리뉴클레오티드의 식별 | |
| RU2014150777A (ru) | Способ индикации наличия или отсутствия рака предстательной железы | |
| CN109081866B (zh) | 癌症中的t细胞亚群及其特征基因 | |
| Hung et al. | Microfluidic platforms for discovery and detection of molecular biomarkers | |
| Mansilla et al. | The identification and isolation of CTCs: a biological Rubik’s cube | |
| Birnie et al. | MicroRNA signatures in malignant pleural mesothelioma effusions | |
| Umelo et al. | Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies | |
| Wahle et al. | IMBAS-MS discovers organ-specific HLA peptide patterns in plasma | |
| Ge et al. | Identification of seven tumor‐educated platelets RNAs for cancer diagnosis | |
| Giarraputo et al. | A changing paradigm in heart transplantation: an integrative approach for invasive and non-invasive allograft rejection monitoring |